Pulse Biosciences Presents Revolutionary nsPFA™ Technology at J.P. Morgan Healthcare Conference 2025

Pulse Biosciences Showcases Innovative Technology at J.P. Morgan Healthcare Conference

Pulse Biosciences, Inc., a pioneering bioelectric medicine company based in Miami, Florida, prepares to present its cutting-edge Nanosecond Pulsed Field Ablation™ (nsPFA™) technology at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Scheduled for January 15, 2025, at 3:45 pm PT, the presentation will be available through a live and recorded webcast on the company's investor website. This event marks a significant platform for Pulse Biosciences to highlight its proprietary CellFX® nsPFA™ technology, which harnesses nanosecond pulses of electrical energy to non-thermally ablate cells while preserving surrounding noncellular tissue.

The nsPFA™ technology has the potential to revolutionize treatment methodologies, particularly in the management of atrial fibrillation, a common heart rhythm disorder. By focusing on precise cellular ablation without damaging adjacent tissues, Pulse Biosciences aims to enhance patient care and outcomes. This innovative approach not only addresses the current limitations of conventional treatments but also offers new avenues for application in various healthcare markets. The company's advancements in bioelectric medicine could significantly change the landscape of how medical procedures are performed, ultimately improving the quality of life for patients.

Pulse Biosciences remains dedicated to its mission of health innovation and is proactively pursuing further developments that can benefit both patients and healthcare providers. With additional offices in Hayward, California, the company is strategically positioned to leverage its technological expertise and expand its market reach. By presenting at a prestigious healthcare conference, Pulse Biosciences underscores its commitment to establishing itself as a leader in bioelectric medicine, delivering solutions that hold the promise of better patient outcomes and refined healthcare practices.

In addition to its innovative technology, Pulse Biosciences holds a portfolio of recognized trademarks, including CellFX, Nano-Pulse Stimulation, and nsPFA, signifying its commitment to quality and innovation in the medical field. The forthcoming presentation at the J.P. Morgan Healthcare Conference not only elevates the company’s visibility within the industry but also emphasizes its role in shaping the future of bioelectric medicine. As Pulse Biosciences continues to advance its technology, the industry watches closely for developments that could transform patient care.